INSIDE, right and then folds out

Reporting adverse reactions

You can report any side effects you may get via **Ireland:** HPRA Pharmacovigilance, Website: www.hpra.ie.
United Kingdom (Northern Ireland): Yellow Card Scheme: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events can also be reported to Takeda at AE.GBR-IRL@takeda.com or via phone call to Takeda UK Ltd - 03333 000181 or Takeda Products Ireland Ltd – 1800 937 970 (freephone from Ireland only) or +44 (0)3333 000181.

Healthcare Professionals - Please also consult the Alunbrig® Summary of Product Characteristics for more information.

Version 3.0 February 2024

BACK COVER

Record your details here:

Your name: _____

Doctor's name (who prescribed Alunbrig®):

_____

Doctor's phone number _____

Hospital _____

Date of first Alunbrig® treatment _____

Date of last Alunbrig® treatment (if you are no longer taking Alunbrig®) _____

IN CASE OF EMERGENCY: please contact:

Name _____

Phone number_____

FRONT COVER

Alunbrig® (brigatinib)

Important

- This patient alert card contains important safety information that you need to be aware of when you are using Alunbrig®.
- Always carry this alert card with you whilst you are receiving treatment and for a month after your last treatment with Alunbrig®.
- Show this card to any doctor or healthcare professional that you see.
- Record your details on the back of this card.

Important information for Patients

Alunbrig® has been given to you to slow down the growth and spread of your lung cancer. When taking Alunbrig® you might get lung or breathing problems.

- Some of the symptoms might be similar to your lung cancer or other lung diseases you may have.
- Some of these are serious and will need immediate medical care.
- These side effects are more likely in the first 7 days after starting your treatment with Alunbrig®.

INSIDE – Left

Important information for Patients

Talk to your doctor straight away if you get any of the following symptoms or if any of these symptoms persist or worsen:

- difficulty breathing
- being short of breath
- pain in your chest
- coughing
- high temperature (fever)

Not all possible side effects are listed on this card

Please read your Alunbrig® package leaflet for more information about side effects.

INSIDE, CENTRE – when flap is opened

Information for Healthcare Professionals

This patient is being treated with Alunbrig® to treat advanced stage ALK+ non-small cell lung cancer.

- Alunbrig® is associated with the occurrence of serious pulmonary adverse reactions such as interstitial lung disease and pneumonitis.
- These pulmonary reactions can occur early, often within the first 7 days of treatment.
- Symptoms of these pulmonary reactions can be confused with symptoms of the patient's underlying pulmonary disease including lung cancer.

Should the patient experience any pulmonary symptoms, **contact the patient's Alunbrig® prescriber** (details in this PAC) straight away to be sure that the correct action is taken.

INSIDE, right – when flap is opened